Skip to content
DraconiticResearch
Search Sources API
189,273 studies31 sourcesUpdated 4 min ago
Peer-reviewedCC BY 4.0PLOS Global Public Health

Cost and transportation barrier trends related to Affordable Care Act among cancer survivors and atherosclerotic cardiovascular disease patients

  1. 1Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, United States of America

Abstract

The Affordable Care Act (ACA) included major coverage expansions implemented in 2014. However, its association with cost‑related barriers among people with chronic disease remains incompletely described. We analyzed trends in cost and transportation related barriers to care between cancer survivors and adults with atherosclerotic cardiovascular disease (ASCVD) in relation to ACA implementation and expansion. National Health Interview Survey (NHIS) data from 2004-2024 for adults ≥18 years reporting a history of cancer or ASCVD without cancer were obtained. Primary outcomes were overall cost‑barrier and transportation barrier. We used survey weighted interrupted time series analysis (ITSA) with prespecified policy breakpoints and survey weighted modified Poisson regression to estimate associations between policy periods and barriers, adjusting for sociodemographic covariates. The analytic sample included 106,947 respondents: 63,505 cancer survivors and 43,442 adults with ASCVD without cancer. Overall cost barriers were reported by 8.1% of cancer survivors (n = 5,264) and 10.6% of adults with ASCVD without cancer (n = 4,772; p < 0.001). In adjusted models, the prevalence of overall cost barriers in 2022–2024 was lower than in 2004–2009 among both cancer survivors (aPR 0.63; 95% CI: 0.56-0.71) and adults with ASCVD without cancer (aPR 0.73; 95% CI: 0.65-0.82). In ITSA, cancer survivors had an immediate decrease in overall cost barriers at the 2022 breakpoint (-1.98 percentage points; p = 0.006). No substantial 2022 level change in overall cost barriers was observed among adults with ASCVD without cancer. Transportation barriers were higher in the post-pandemic period among years with available data, particularly among adults with ASCVD without cancer, but transportation ITSA findings were exploratory since data were unavailable in 2019–2021. Overall cost related barriers declined among U.S. cancer survivors and ASCVD patients, with the largest improvements observed in the most recent period. Nevertheless, increases in transportation-related delays underscore persistent structural barriers and highlight the need for targeted interventions to improve care accessibility.

Related

  1. When Is Tracking Affordable? A Movement-Budget Feasibility Threshold for Dynamic Regret
    Ridham Patel
    arXivPreprintCC BY 4.0Full textOptimisation & controlStatisticsarXiv
  2. First round of lung cancer screening among patients with atheromatous cardiovascular disease exposed to tobacco: a prospective cohort study
    Elsa Armand, Clarisse Buton, Caroline Caramella +36
    Respiratory Medicine and ResearchPeer-reviewedCC BY 4.0Full textStatisticsHAL
  3. Stability under mixtures of transportation inequalities and restricted log-Sobolev inequalities
    Radosław Adamczak, Dominik Kutek, Michał Strzelecki
    arXivPreprintCC BY-NC-ND 4.0Full textAnalysis & PDEsProbabilityarXiv
  4. Directional Nonlinear Principal Components: a measure transportation approach
    Marc Hallin, Klaus Nordhausen, Una Radojicic
    arXivPreprintarXiv licenceFull textStatisticsarXiv
  5. Reverse Transportation and Harnack Inequalities for Underdamped Langevin in the Non-convex Setting
    Andreas Habring, Laurenz Nagler
    arXivPreprintCC BY 4.0Full textProbabilityarXiv
BibTeX
@article{bega2026cost,
  title = {{Cost and transportation barrier trends related to Affordable Care Act among cancer survivors and atherosclerotic cardiovascular disease patients}},
  author = {Rabia Bega and Qaidar Alizai and Charalampos M. Charalampous and Areesh Mevawalla and Meher Angez and Rida Ejaz and Lorenza Arena and Jethro Wang Zih-Shuo and Timothy M. Pawlik},
  journal = {PLOS Global Public Health},
  year = {2026},
  month = sep,
  doi = {10.1371/journal.pgph.0006791},
  url = {https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0006791},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Cost and transportation barrier trends related to Affordable Care Act among cancer survivors and atherosclerotic cardiovascular disease patients
AU  - Rabia Bega
AU  - Qaidar Alizai
AU  - Charalampos M. Charalampous
AU  - Areesh Mevawalla
AU  - Meher Angez
AU  - Rida Ejaz
AU  - Lorenza Arena
AU  - Jethro Wang Zih-Shuo
AU  - Timothy M. Pawlik
PY  - 2026
DA  - 2026/09/18
JO  - PLOS Global Public Health
DO  - 10.1371/journal.pgph.0006791
UR  - https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0006791
AB  - The Affordable Care Act (ACA) included major coverage expansions implemented in 2014. However, its association with cost‑related barriers among people with chronic disease remains incompletely described. We analyzed trends in cost and transportation related barriers to care between cancer survivors and adults with atherosclerotic cardiovascular disease (ASCVD) in relation to ACA implementation and expansion. National Health Interview Survey (NHIS) data from 2004-2024 for adults ≥18 years reporting a history of cancer or ASCVD without cancer were obtained. Primary outcomes were overall cost‑barrier and transportation barrier. We used survey weighted interrupted time series analysis (ITSA) with prespecified policy breakpoints and survey weighted modified Poisson regression to estimate associations between policy periods and barriers, adjusting for sociodemographic covariates. The analytic sample included 106,947 respondents: 63,505 cancer survivors and 43,442 adults with ASCVD without cancer. Overall cost barriers were reported by 8.1% of cancer survivors (n = 5,264) and 10.6% of adults with ASCVD without cancer (n = 4,772; p < 0.001). In adjusted models, the prevalence of overall cost barriers in 2022–2024 was lower than in 2004–2009 among both cancer survivors (aPR 0.63; 95% CI: 0.56-0.71) and adults with ASCVD without cancer (aPR 0.73; 95% CI: 0.65-0.82). In ITSA, cancer survivors had an immediate decrease in overall cost barriers at the 2022 breakpoint (-1.98 percentage points; p = 0.006). No substantial 2022 level change in overall cost barriers was observed among adults with ASCVD without cancer. Transportation barriers were higher in the post-pandemic period among years with available data, particularly among adults with ASCVD without cancer, but transportation ITSA findings were exploratory since data were unavailable in 2019–2021. Overall cost related barriers declined among U.S. cancer survivors and ASCVD patients, with the largest improvements observed in the most recent period. Nevertheless, increases in transportation-related delays underscore persistent structural barriers and highlight the need for targeted interventions to improve care accessibility.
SN  - 2767-3375
ER  -